Aquestive Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2018 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Aquestive Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2018 to Q1 2024.
  • Aquestive Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $81.7M.
  • Aquestive Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $3.97M, a 65.7% decline from 2022.
  • Aquestive Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $11.6M, a 61.5% decline from 2021.
  • Aquestive Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $30.1M, a 5.81% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $81.7M +$90.9M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q1 2023 -$9.21M -$10.5M -809% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q1 2022 $1.3M -$8.59M -86.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q1 2021 $9.89M +$9.93M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q1 2020 -$37K +$2.57M +98.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q1 2019 -$2.61M -$1.19M -84.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q1 2018 -$1.42M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.